Neuronal TGase (TG6) ELISA

ZediXclusive TG6-ab ELISA (IgG)


Neuronal transglutaminase (TG6) ELISA IgG

Order
Quantity
Price
Status
1 Kit/96 wells 520 € available


Documents
Art. No. E104
Background info The TG6-ab ELISA (IgG) kit with the Zedira product number E104 is the revised version of kit TG6-ab ELISA (IgG) with the product number E004.

Autoantibodies directed against neuronal transglutaminase (TG6) may occur in the sera of patients suffering from neurological disorders like e.g. ataxia, neuropathy, cerebral pulsy or stiffperson syndrome.
Autoantibodies to TG6 can be found in addition to TG2-autoantibodies in celiac patients, but were also found in TG2-autoantibody negative sera and in sera from patients without enteropathy (non-celiac patients). Therefore antibodies to TG6 may develop independent from celiac disease.
Assay principle The wells of the solid phase are coated with TG6.
1st reaction: TG6-specific antibodies present in the sample bind to the immobilised antigen, forming the antigen-antibody complex.
2nd reaction: A second antibody, directed at human IgG antibodies and labeled with horse-radish peroxidase (HRP), binds to the complex.
3rd reaction: The enzyme-labelled complex converts a substrate into a blue product. Samples containing IgG antibodies against TG6 develop the blue colour, whereas samples without these antibodies remain colourless.
Intended use The present Enzyme-Linked Immuno Sorbent Assay (ELISA) is intended for the quantitative or qualitative determination of IgG antibodies in human serum, directed against TG6. The immobilised antigen is a highly purified preparation of human recombinant TG6. The test is fast (incubation time 30 / 30 / 30 minutes) and flexible (divisible solid phase, ready-to-use reagents). Six calibrators allow quantitative measurements; a negative and a positive control check the assay performance.
Storage Store kit at 2 - 8°C. It is stable up to the expiry date stated on the label of the box. Do not use kit beyond its expiry date.
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • MEDICA

    13.11.2017 - 16.11.2017
    Düsseldorf, Germany

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland